I-Med Pharma Partners With OcuSoft for U.S. Distribution of Dry Eye Screening Tool
Tuesday, January 9, 2018 12:12 AM
MONTREAL—I-Med Pharma Inc.
, a Canadian company specializing in dry eye diagnosis and management, has signed an exclusive agreement with OcuSoft Inc.
for the U.S. distribution rights of its patented I-Pen Osmolarity System. According to I-Med, I-Pen is the first, handheld platform to offer ECPs a “quick and reliable tool for screening dry eye patients.” In an announcement Monday, I-Med noted that the FDA accepted its 510k filing for the I-Pen Osmolarity System and that the distribution partnership will “officially commence upon final FDA approval of the 510k.” This approval is anticipated in the first quarter of 2018, according to the announcement.
“We are thrilled to partner with OcuSoft, a company recognized for addressing clinical needs with innovative solutions,” I-Med president Daniel Hofmann said in the announcement. “The I-pen Osmolarity System is an invaluable asset for measuring tear osmolarity, a key step in identifying the presence and severity of dry eye disease.”
He added that the companies expect the new partnership “will offer the first economical solution for eyecare professionals looking for an efficient and reliable diagnostic tool in this area.”
OcuSoft is a privately held Richmond, Texas-based research, development and supply company specializing in eye and skin care.